1. Introduction {#s0005}
===============

The desire for better individualized treatment for hypothyroid patients has led to research to clarify the role of genetic polymorphisms on L-T4 bioavailability. P-gp is a well-known transport protein found mostly in the cellular membrane of different cell types in the intestine, kidney, blood-brain barrier and parathyroid glands ([@b0225], [@b0040]). P-gp, an ATP-dependent efflux transporter, acts as a physiological barrier by extruding a wide range of substances, from xenobiotics to endogenous compounds such as pesticides, anticancer drugs, antibiotics, cardiac glycosides, small proteins and hormones ([@b0215]). P-gp is encoded by the *MDR1* gene, which is located in the region 7q21.12 of chromosome 7 in humans ([@b0235]).

*MDR1* has a crucial role in drug disposition, and genetic polymorphisms in this gene might alter the pharmacokinetics and bioavailability of a diverse range of P-gp substrates ([@b0135]). Although many variations in the coding region of *MDR1* have been found, there is no consensus on their implications at the clinical level ([@b0130], [@b0180], [@b0150]). So far, approximately one hundred single nucleotide polymorphisms (SNPs) in *MDR1* have been identified ([@b0160]). Among all variations, C1236T (rs1128503, Gly412Gly), G2677T/A (rs2032582, Ser893Ala/Thr) and C3435T (rs1045642, Ile1145Ile) are common and have a different prevalence in different groups of the population ([@b0110]).

L-T4, a synthetic T4 hormone, is the first choice for the treatment of hypothyroidism, which is characterized by decreased levels of the circulating thyroid hormones triiodothyronine (T3) and its prohormone thyroxine (T4), which are secreted from the thyroid gland by stimulation from thyroid stimulating hormone (TSH) ([@b0230], [@b0175]). L-T4 is usually administered 100--150 mcg/day for men and 75--100 mcg/day for women ([@b0155]); dose adjustment is made by a trial and error approach. However, besides age, gender, concurrent diseases and polypharmacy, genetic background may have a significant effect on the bioavailability of L-T4 treatment as well ([@b0090], [@b0015]).

Since drug efflux is mediated by P-gp, *MDR1* polymorphisms play an important role in cell homeostasis by altering bioavailability of L-T4 and regulating the thyroid hormone levels. In the present study, we aimed to investigate the association between *MDR1* variants and thyroid function parameters in patients with L-T4 treatment. This study is the first that evaluates the effects of *MDR1* polymorphisms on L-T4 dose adjustment.

2. Material and methods {#s0010}
=======================

2.1. Subjects {#s0015}
-------------

The study was conducted as a cross-sectional study with Turkish participants recruited from endocrine surgery clinics of Istanbul University Istanbul Medical Faulty between March 2015 and October 2016. Ninety patients with secondary hypothyroidism caused by total thyroidectomy were included. All patients received various doses of L-T4, adjusted by the practitioners with regard to the patient's body mass index and level of thyroid function parameters. The study was approved by the ethical committee of Istanbul University (2015/740) and carried out in accordance with the Helsinki Declaration of 1975. All participants were provided informed consent.

2.2. Biochemical analysis {#s0020}
-------------------------

TSH, fT3 and fT4 levels were measured in biochemistry laboratories of the Medical School of Istanbul University by performing GenWay Biotech Inc. (San Diego, CA, USA) ELISA kits according to manufacturer's instructions.

2.3. Genotyping {#s0025}
---------------

DNA was isolated from venous blood samples using the High Pure PCR Template Preparation Kit (Roche, Germany) and kept at 4 °C. Genotyping was done by the LightCycler FastStart DNA Master HybProbe and Roche LightSNP assay probes (Roche, Germany) according to the manufacturer's instructions. In a final volume of 20 µL reaction mix per sample, the following mixtures was added: 1X FastStart DNA Master Mix, 2 mM MgCl~2~, 0.2 µM LightSNP HybProbe, appropriate amount of PCR grade water and 500 ng DNA sample. The plates were sealed and centrifuged at 3000 rpm for a minute. Melting curve analyses were performed on a real-time PCR platform (LightCycler 480, Roche, Germany) by the Carousel-Based System PCR program ([Table 1](#t0005){ref-type="table"}). In each plate, sterile water and a known genotyped sample were used as controls to achieve 100% concordance.Table 1Carousel-Based System PCR program setup.Program nameCyclesAnalysis modeTarget (°C)Acquisition modeHold (sec)Pre-Incubation1None95None600Amplification45Quantification95None1060Single1072None15Melting Curve1Melting Curve95None3040None12075Continuous--Cooling1None40None30

2.4. Statistical analysis {#s0030}
-------------------------

All statistical analyses were carried out by using Statistical Package for Social Sciences (SPSS) software (Version 21, Chicago, USA). Hardy-Weinberg equilibrium was tested using the chi-square. Data were expressed as median, minimum, maximum, frequencies and percentages. Genotypes were evaluated with the Mann-Whitney *U* test. The association between genotypes and L-T4 dose were assessed using binary logistic regression while TSH, fT3, fT4, age and BMI were covariates. Haplotypes were identified by a Bayesian approach using the PHASE algorithm (Version 2, Chicago, USA). A two-tailed value of *p* \< .05 was considered a statistically significant difference.

3. Results {#s0035}
==========

*MDR1* C1236T, G2677T/A, and C3435T variants were evaluated in Turkish patients with secondary hypothyroidism. All samples (n = 90) were genotyped with at least a 96.7% success rate and 100% concordance. Genotype distribution was found to be consistent with the Hardy-Weinberg equilibrium model (*p* \> .05), suggesting that the studied population was unbiased. Features of the studied SNPs are summarized in [Table 2](#t0010){ref-type="table"}. Allele frequencies were found notably similar to Caucasians as stated in the NCBI SNP database (dbSNP, <https://www.ncbi.nlm.nih.gov/snp>).Table 2Genotype distribution and features of studied SNPs.SNPAmino acid changeVariant alleleGenotypen (%)MAFHWEC1236TGly412GlyTCC25 (27.8)0.480.04CT41 (45.6)TT22 (24.4)  G2677T/ASer893Ala/ThrT/AGG10 (11.1)0.51\<0.01AG13 (14.4)TG40 (44.4)TT24 (26.7)  C3435TIle1145IleTCC22 (24.4)0.510.02CT45 (50.0)TT23 (25.6)[^1]

The clinical and biochemical characteristics of the patients are summarized in [Table 3](#t0015){ref-type="table"}. The median age was 51.35 (21--76) years, the median body mass index (BMI, kg/m^2^) was 29.06 (19.72--38.58), and females represented 83.3% of the participants. The median values of thyroid hormones were 0.96 mIU/L for TSH (reference range: 0.4--4 mIU/L), 4.95 pmoL/L for fT3 (reference range: 3.5--7.8 pmol/L) and 19.54 pmoL/L for fT4 (reference range: 9--25 pmol/L) ([@b0065]).Table 3Clinical and biochemical characteristics of the patients.VariableMedian (Range)Age51.35 (21--76)BMI (kg/m^2^)29.06 (19.72--38.58)Gender Female (n, %)75 (83.3%) Male (n, %)15 (16.7%)L-T4 (mcg/day)118.02 (50--250)TSH (mIU/L)0.96 (0.01--12.20)fT3 (pmol/L)4.95 (0.80--22.07)fT4 (pmol/L)19.54 (2.20--29.11)

The L-T4 dose distribution among genotypes, based on a dominant model comparing wild-type homozygous versus others, is illustrated in [Fig. 1](#f0005){ref-type="fig"}. The median L-T4 dose was observed much the same among the genotypes in each SNP. Additionally, binary logistic regression analysis showed that the selected SNPs had no influence on the L-T4 dose adjustment while TSH, fT3, fT4, BMI and age were covariates ([Table 4](#t0020){ref-type="table"}).Fig. 1L-T4 dose distribution among genotypes. Red lines represent median L-T4 doses (µg/day) and values were shown as median (range) above the related columns. n, number of patients.Table 4Effects of genotypes on L-T4 doses.SNPGenotypeBSEOR (95% CI)*p*C1236TCC vs. CT + TT−0.0110.0090.989 (0.972--1.006)0.21G2677T/AGG vs. others0.0100.0151.01 (0.982--1.039)0.49C3435TCC vs. CT + TT−0.0160.0090.984 (0.967--1.002)0.08[^2]

Seven haplotypes were observed and two major haplotypes, T~1236~T~2677~T~3435~ and C~1236~G~2677~C~3435~, were identified that accounted for 82.8% of all patients ([Fig. 2](#f0010){ref-type="fig"}). The remaining haplotypes were observed in up to 7 patients; hence, association between two major haplotypes and L-T4 dose was examined. Binary logistic regression showed that T~1236~T~2677~T~3435~ (n = 33; OR \[95% CI\] = 1.010 \[0.983--1.038\]; p = .479) and C~1236~G~2677~C~3435~ (n = 29; OR \[95% CI\] = 0.993 \[0.969--1.017\]; p = .542) haplotypes had no influence on the L-T4 dose adjustment while TSH, fT3, fT4, age and BMI were covariates.Fig. 2*MDR1* haplotypes and frequencies based on C1236T/G2677T/C3435T genotypes identified by PHASE algorithm.

4. Discussion {#s0040}
=============

In the complex balance of body homeostasis, thyroid hormones play crucial roles in several metabolic pathways, such as protein, carbohydrate and fat metabolism, through regulation of the endocrine system. Thyroid hormones exert their action on nuclear receptors; thus, the equilibrium of thyroid hormones in cells is a major component for proper body development ([@b0175]). For patients with hypothyroidism, L-T4 is a commonly prescribed drug for hormone replacement therapy which aims to normalize serum TSH level. The success of the treatment depends on L-T4 bioavailability, which is affected by several factors such as timing of administration ([@b0025]), body mass ([@b0205]), gender ([@b0070]), age and concurrent diseases ([@b0090]), pregnancy, cytochrome P450 enzyme inducers ([@b0195]), and genetic polymorphisms ([@b0010]).

It is well established that *MDR1* encodes the membrane transporter P-glycoprotein (P-gp) which alters the disposition of a great variety of structurally unrelated substances and therefore has a great impact on drug bioavailability ([@b0045], [@b0080], [@b0020]). *MDR1* has been found to be highly polymorphic in various populations ([@b0115], [@b0050], [@b0030]), yet the clinical implications remain uncertain. C1236T, G2677T/A and C3435T variants are the most studied SNPs due to their high frequencies in Caucasians and Asians ([@b0085]). C1236T and C3435T are silent SNPs, whereas G2677T/A results in an amino acid change ([@b0190]). An interesting fact about these SNPs is that they are in linkage disequilibrium ([@b0110]), meaning that they occur together and it is difficult to study them separately.

[@b0165] observed increased exposure to irinotecan in patients diagnosed with malignant solid tumors with the 1236 TT genotype. [@b0255] reported that cyclosporine concentrations were greater in myasthenia gravis patients with 1236 TT or 2677 TT genotypes, whereas [@b0210] found increased response of temozolomide treatment in glioblastoma patients with the 1236 CC genotype. [@b0125] reported that the 2677 TT and 3435 TT genotypes were associated with decreased plasma concentration of fexofenadine in healthy subjects; however, [@b0250] reported that 2677 TT genotype was associated with increased tacrolimus neurotoxicity in liver transplantation patients. [@b0115] reported that the 3435 TT genotype was associated with higher plasma concentrations of digoxin. In contrast, [@b0185] reported lower plasma concentrations of atazanavir. Additionally, [@b0260], [@b0095] found that the 3435 TT genotype was associated with increased levels of nelfinavir in HIV-positive patients.

Although many researchers reported controversial associations with numerous drugs, there is a substantial opinion that suggests these SNPs have no effect on drug pharmacokinetics. C3435T is not associated with digoxin and fexofenadine concentrations in healthy subjects ([@b0035], [@b0075]), or with changes in cyclosporine and tacrolimus concentrations in renal transplant patients ([@b0105]). Moreover, [@b0060] reported that the C1236T, G2677T/A and C3435T variants had no effect on lopinavir and ritonavir concentrations in HIV-infected men. Similarly, [@b0145] found that these SNPs are not associated with phenytoin, carbamazepine, phenobarbital, and valproate response in North Indian epileptic patients.

There are limited studies evaluating the relationship between *MDR1* polymorphisms and L-T4 administration. [@b0170], [@b0120] reported that P-gp is induced by long-term L-T4 administration in human colon carcinoma cell lines and Wistar rats, respectively. [@b9000] conducted a study with a limited number of human subjects who had normal thyroid functions and found that L-T4 administration caused *MDR1* upregulation. In the same study, no modulation by the C3435T polymorphism was observed, in contrast to the study by [@b0115] who reported that the C3435T polymorphism does impact *MDR1* upregulation. However, the G2677T/A polymorphism was found to be associated with lower levels of L-T4. There are no previous studies regarding the effects of *MDR1* polymorphisms on L-T4 dose adjustment in patients with hypothyroidism. In the present study, no association was observed between the C1236T, G2677T/A or C3435T genotypes and the L-T4 dose that was required to achieve favorable thyroid hormone levels.

Haplotype analysis was conducted due to previous reports indicating that these three SNPs are closely linked in many populations. In the present study, two major haplotypes, T~1236~T~2677~T~3435~ and C~1236~G~2677~C~3435~in agreement with [@b0125], [@b0220], [@b0140]. Finally, the clinical outcomes of *MDR1* haplotypes are controversial regarding a wide range of drugs in different populations. [@b0200] reported that the T~1236~T~2677~T~3435~ haplotype was associated with an increased concentration of irinotecan in Japanese cancer patients. [@b0055] reported that Asian heart transplantation patients with the T~1236~T~2677~T~3435~haplotype had a higher concentration of cyclosporine. Additionally, [@b0005], [@b0240] found that the T~1236~T~2677~T~3435~haplotype, but not the CGC haplotype, was associated with increased digoxin exposure in Europeans and Chinese, respectively. However, [@b0145], [@b0245] observed that none of the *MDR1* haplotypes were associated with drug concentrations. Similarly, in the present study, neither the T~1236~T~2677~T~3435~nor the C~1236~G~2677~C~3435~ haplotype was found to be associated with L-T4 dose adjustment in hypothyroid patients.

5. Conclusion {#s0045}
=============

In this first cross-sectional study conducted with secondary hypothyroidism patients, no association was found between L-T4 dose administration and the C1236T, G2677T/A, C3435T genotypes and haplotypes. In consideration of conflicted previous reports regarding the genetic contribution of *MDR1* to drug disposition, further studies are required to clarify the influence.
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[^1]: MAF, Minor allele frequency; HWE, Hardy-Weinberg equilibrium.

[^2]: B, Coefficient for the constant; SE, Standard error; OR, Odds ratio; CI, Confidence interval.
